HCW Cash Ratio from 2010 to 2024

HCWB Stock  USD 1.07  0.02  1.90%   
HCW Biologics' Cash Ratio is decreasing over the years with slightly volatile fluctuation. Cash Ratio is expected to dwindle to 0.39. From 2010 to 2024 HCW Biologics Cash Ratio quarterly data regression line had arithmetic mean of  6.06 and r-squared of  0.31. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
0.41098024
Current Value
0.39
Quarterly Volatility
2.39109865
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 660.3 K or Interest Expense of 201.3 K, as well as many indicators such as Price To Sales Ratio of 30.12, Dividend Yield of 0.0 or PTB Ratio of 3.12. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
  
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

Latest HCW Biologics' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of HCW Biologics over the last few years. It is HCW Biologics' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HCW Biologics' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

HCW Cash Ratio Regression Statistics

Arithmetic Mean6.06
Geometric Mean4.71
Coefficient Of Variation39.48
Mean Deviation1.64
Median6.90
Standard Deviation2.39
Sample Variance5.72
Range8.0567
R-Value(0.56)
Mean Square Error4.22
R-Squared0.31
Significance0.03
Slope(0.30)
Total Sum of Squares80.04

HCW Cash Ratio History

2024 0.39
2023 0.41
2022 7.55
2021 5.05
2020 8.45

About HCW Biologics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include HCW Biologics income statement, its balance sheet, and the statement of cash flows. HCW Biologics investors use historical funamental indicators, such as HCW Biologics's Cash Ratio, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may use each financial statement separately, they are all related. The changes in HCW Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on HCW Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on HCW Biologics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Ratio 0.41  0.39 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in HCW Stock

When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.76)
Revenue Per Share
0.108
Quarterly Revenue Growth
25.901
Return On Assets
(0.47)
Return On Equity
(1.32)
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.